This company has been acquired
IVERIC bio Future Growth
Future criteria checks 5/6
IVERIC bio is forecast to grow earnings and revenue by 59% and 58% per annum respectively. EPS is expected to grow by 61.5% per annum. Return on equity is forecast to be -21.7% in 3 years.
Key information
59.0%
Earnings growth rate
61.5%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 58.0% |
| Future return on equity | -21.7% |
| Analyst coverage | Good |
| Last updated | 23 Jun 2023 |
Recent future growth updates
Recent updates
Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate
Sep 06IVERIC bio Q2 2022 Earnings Preview
Jul 25Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura
Jul 05IVERIC bio: A First Take
Jun 23Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
Sep 16IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses
Jun 18IVERIC bio EPS misses by $0.04
May 05IVERIC bio EPS misses by $0.05
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 365 | -28 | 57 | N/A | 9 |
| 12/31/2024 | 124 | -200 | -131 | -154 | 9 |
| 12/31/2023 | 11 | -281 | -212 | -236 | 8 |
| 3/31/2023 | N/A | -223 | -178 | -177 | N/A |
| 12/31/2022 | N/A | -185 | -165 | -164 | N/A |
| 9/30/2022 | N/A | -159 | -138 | -137 | N/A |
| 6/30/2022 | N/A | -141 | -123 | -122 | N/A |
| 3/31/2022 | N/A | -122 | -107 | -107 | N/A |
| 12/31/2021 | N/A | -115 | -99 | -99 | N/A |
| 9/30/2021 | N/A | -107 | -97 | -97 | N/A |
| 6/30/2021 | N/A | -108 | -86 | -86 | N/A |
| 3/31/2021 | N/A | -96 | -78 | -78 | N/A |
| 12/31/2020 | N/A | -85 | -66 | -66 | N/A |
| 9/30/2020 | N/A | -77 | -57 | -57 | N/A |
| 6/30/2020 | N/A | -66 | -54 | -54 | N/A |
| 3/31/2020 | N/A | -61 | -51 | -51 | N/A |
| 12/31/2019 | N/A | -59 | -48 | -48 | N/A |
| 9/30/2019 | N/A | 63 | -47 | -47 | N/A |
| 6/30/2019 | N/A | 62 | -45 | -45 | N/A |
| 3/31/2019 | N/A | 64 | -44 | -44 | N/A |
| 12/31/2018 | N/A | 63 | -42 | -42 | N/A |
| 9/30/2018 | N/A | -51 | -45 | -45 | N/A |
| 6/30/2018 | 207 | 153 | -50 | -50 | N/A |
| 3/31/2018 | 208 | 144 | -72 | -72 | N/A |
| 12/31/2017 | 210 | 114 | -122 | -122 | N/A |
| 9/30/2017 | 215 | 57 | -142 | -141 | N/A |
| 6/30/2017 | 10 | -192 | -132 | -131 | N/A |
| 3/31/2017 | 37 | -200 | -134 | -133 | N/A |
| 12/31/2016 | 51 | -193 | N/A | -109 | N/A |
| 9/30/2016 | 50 | -163 | N/A | -115 | N/A |
| 6/30/2016 | 52 | -141 | N/A | -133 | N/A |
| 3/31/2016 | 26 | -149 | N/A | -84 | N/A |
| 12/31/2015 | 52 | -106 | N/A | -79 | N/A |
| 9/30/2015 | 48 | -102 | N/A | -29 | N/A |
| 6/30/2015 | 85 | -54 | N/A | -50 | N/A |
| 3/31/2015 | 83 | -89 | N/A | 96 | N/A |
| 12/31/2014 | 41 | -117 | N/A | 111 | N/A |
| 9/30/2014 | 40 | -106 | N/A | 75 | N/A |
| 6/30/2014 | N/A | -132 | N/A | 107 | N/A |
| 3/31/2014 | N/A | -71 | N/A | -61 | N/A |
| 12/31/2013 | N/A | -57 | N/A | -49 | N/A |
| 9/30/2013 | N/A | -42 | N/A | -27 | N/A |
| 6/30/2013 | N/A | -30 | N/A | -18 | N/A |
| 3/31/2013 | N/A | -23 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ISEE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: ISEE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ISEE is expected to become profitable in the next 3 years.
Revenue vs Market: ISEE's revenue (58% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: ISEE's revenue (58% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ISEE is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/12 16:26 |
| End of Day Share Price | 2023/07/10 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IVERIC bio, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Ling Wang | BTIG |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |